Linsitinib (OSI-906)

For research use only.

Catalog No.S1091

91 publications

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 186 In stock
EUR 167 In stock
EUR 265 In stock
EUR 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Linsitinib (OSI-906) has been cited by 91 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnndJNrUUN3ME2wMlAzQDB4IN88US=> M1XBV3NCVkeHUh?=
KS-1 NXOzXW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\FNWlEPTB;MD6wN|g{PSEQvF2= MU\TRW5ITVJ?
TE-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S4OmlEPTB;MD6wO|gzOiEQvF2= NEm2dZVUSU6JRWK=
EW-1 NIW1PVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\vdpVEUUN3ME2wMlA5PTh3IN88US=> M1zCUXNCVkeHUh?=
HMV-II MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnTfG1KSzVyPUCuNFg5PDZizszN NYDVdItDW0GQR1XS
COLO-205 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMUC0OVQh|ryP M3jKRnNCVkeHUh?=
ES1 M2[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjzOGhkUUN3ME2wMlExPjl4IN88US=> NXLicZVSW0GQR1XS
GDM-1 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\iWXlSUUN3ME2wMlE{Pjd{IN88US=> MoXEV2FPT0WU
ML-2 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPFTWM2OD1yLkG1PFk3KM7:TR?= M4OxNnNCVkeHUh?=
Saos-2 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCeWlEPTB;MD6xOlUzPiEQvF2= MnvXV2FPT0WU
NCI-H1355 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMUixN|Uh|ryP Moe1V2FPT0WU
G-401 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjCbm9KSzVyPUCuNVgzOyEQvF2= NH6yT21USU6JRWK=
EW-16 NXrPdG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT6Umh1UUN3ME2wMlE5Pzd5IN88US=> MWTTRW5ITVJ?
EW-7 NHfsW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW3ZlNjUUN3ME2wMlE5QDhzIN88US=> NVjKZVFOW0GQR1XS
NCI-H727 NXLONldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnFTWM2OD1yLkG5O|k1KM7:TR?= NWraNYVqW0GQR1XS
LCLC-97TM1 NEfodFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzPWlEPTB;MD6yNFk2PSEQvF2= MXXTRW5ITVJ?
NCI-H650 NVPMeol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMkGzPFQh|ryP Mn\OV2FPT0WU
NCI-H2122 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfGTWM2OD1yLkKzNlk6KM7:TR?= NXSyWWVrW0GQR1XS
SK-N-DZ NHWyflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PtXWlEPTB;MD6yN|Y6QCEQvF2= MkSxV2FPT0WU
HT-29 NIrGfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyzTWM2OD1yLkK0NlQ5KM7:TR?= M3XORnNCVkeHUh?=
LB771-HNC M1v6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLCVXZYUUN3ME2wMlI2QTF3IN88US=> NFHUfppUSU6JRWK=
HT-144 M3zEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vBcGlEPTB;MD6yOlE6OSEQvF2= NF7xNmpUSU6JRWK=
LAN-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf5NGRKSzVyPUCuNlY{PDhizszN NGLORVRUSU6JRWK=
EW-18 M4DzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkewNFEh|ryP MVrTRW5ITVJ?
LS-1034 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjLTWM2OD1yLkK3NVMzKM7:TR?= NF75VpNUSU6JRWK=
EW-11 NFfweoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf5fYZwUUN3ME2wMlI5PDN{IN88US=> MkjvV2FPT0WU
SNU-C1 NXz4T|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fMOGlEPTB;MD6yPVMyOyEQvF2= MYLTRW5ITVJ?
RS4-11 NHLr[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkNWlEPTB;MD6zN|c2QCEQvF2= M4n2eHNCVkeHUh?=
ES4 M2T0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;VTWM2OD1yLkSxNFM5KM7:TR?= M2PEenNCVkeHUh?=
COLO-320-HSR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r4OWlEPTB;MD60NVM3QCEQvF2= MWjTRW5ITVJ?
NB10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X1SGlEPTB;MD60OVQ{PyEQvF2= NXjRUodGW0GQR1XS
BFTC-905 M1q3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;xUXk{UUN3ME2wMlQ3PzV6IN88US=> MVLTRW5ITVJ?
A375 M1fnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HNOGlEPTB;MD60O|YyPyEQvF2= M3SzUnNCVkeHUh?=
SJRH30 NVjqXpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNUC4NlIh|ryP NX\lZ5Q3W0GQR1XS
NOS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrhZYNSUUN3ME2wMlUzOjZ5IN88US=> NHPz[ZZUSU6JRWK=
SIG-M5 M3fQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNUO1OVch|ryP M{n5[nNCVkeHUh?=
DOK M{TNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofLTWM2OD1yLkW1OkDPxE1? NXTScmhTW0GQR1XS
NB69 NYrtbldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe0b4ZVUUN3ME2wMlU5OjV5IN88US=> MVLTRW5ITVJ?
SK-NEP-1 NUCxVWlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNkCyN|Yh|ryP NYqyOZZNW0GQR1XS
SK-MM-2 M1nYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNkW0PVEh|ryP M{PtbXNCVkeHUh?=
NCI-H358 NWLy[olkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP1UJk5UUN3ME2wMlY4ODh{IN88US=> MVTTRW5ITVJ?
RH-1 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL4TWM2OD1yLke0PFU6KM7:TR?= NXLpd25sW0GQR1XS
NH-12 NHOyU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnhTWM2OD1yLke2NFQ3KM7:TR?= MlLvV2FPT0WU
TE-12 M3fFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwN{[0PFYh|ryP Mme1V2FPT0WU
COLO-668 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrJOnBZUUN3ME2wMlg1PjZ4IN88US=> MVrTRW5ITVJ?
PANC-08-13 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPJTWM2OD1yLki2N|c4KM7:TR?= NEi1OlBUSU6JRWK=
HCC2998 M1m2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPn[JpPUUN3ME2wMlg5OjZ|IN88US=> NGrBOHVUSU6JRWK=
ABC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe2XHVKSzVyPUCuPVA{PTJizszN M2TtTHNCVkeHUh?=
ES6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTDfIdVUUN3ME2wMlkyODZ4IN88US=> NWTySXJJW0GQR1XS
SNU-387 NGnJNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH74flhKSzVyPUCuPVk{QTNizszN MU\TRW5ITVJ?
CMK NVvoWWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XzdWlEPTB;MD65PVkzQSEQvF2= MknEV2FPT0WU
SJSA-1 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMEO2OVMh|ryP NHXn[nJUSU6JRWK=
SIMA MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHlXZdKSzVyPUGuNFY5OjVizszN NHvrOndUSU6JRWK=
ES3 NFLhR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\DOGlEPTB;MT6xNlI6PyEQvF2= M{D1SHNCVkeHUh?=
IGROV-1 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLUdWE1UUN3ME2xMlE2PDR2IN88US=> NXfLTpVLW0GQR1XS
MEL-JUSO NV;3ZZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\sTWM2OD1zLkG1O|U6KM7:TR?= MXnTRW5ITVJ?
T84 NF3YUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwMkC5NVQh|ryP M3m1UHNCVkeHUh?=
CAL-85-1 M{HV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LVSWlEPTB;MT6yN|E{QCEQvF2= Mni2V2FPT0WU
RD MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomxTWM2OD1zLkK2OFU2KM7:TR?= MUTTRW5ITVJ?
TE-8 NYf1[IFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv1TWM2OD1zLkOxOFYzKM7:TR?= Mo\2V2FPT0WU
L-363 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7FTWM2OD1zLkO0NlA5KM7:TR?= NW\aVXM4W0GQR1XS
EKVX M{PSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq0TWM2OD1zLkO0OVY5KM7:TR?= NXLMNmVQW0GQR1XS
SK-MEL-3 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7WPWttUUN3ME2xMlQ5PTV4IN88US=> MV7TRW5ITVJ?
TGBC24TKB NETRU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSwTWM2OD1zLkWwNVk{KM7:TR?= MmW0V2FPT0WU
NCI-H1770 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwNUGxNVMh|ryP NXL4TXVjW0GQR1XS
HuH-7 M2C2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOwXWZKSzVyPUGuOlAxQThizszN M2nUWXNCVkeHUh?=
HL-60 NXvvToE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X5VmlEPTB;MT62OlkzQCEQvF2= MW\TRW5ITVJ?
TE-1 NGfvbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwN{C5OFUh|ryP MYHTRW5ITVJ?
LC-2-ad M2D2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwN{O4PFch|ryP NWrVfHVPW0GQR1XS
LB647-SCLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nUWWlEPTB;MT63OlU5OyEQvF2= NV\YU2FxW0GQR1XS
NCI-H2171 NGT4UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPNXpRKSzVyPUGuO|c4OTZizszN NWW2RWQxW0GQR1XS
SK-PN-DW NWfKcY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsTWM2OD1zLkmxNlk5KM7:TR?= NEHqNpVUSU6JRWK=
MC-IXC NXzyc21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mwXWlEPTB;MT65PFk5KM7:TR?= NHP5VW5USU6JRWK=
LS-513 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm5WnI5UUN3ME2yMlA2OzB3IN88US=> NXjaNWdYW0GQR1XS
EW-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuOGlEPTB;Mj6wPVg1PCEQvF2= MXHTRW5ITVJ?
OPM-2 NYrlR3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ywVGlEPTB;Mj6xNFIh|ryP NG\adJBUSU6JRWK=
LP-1 M1;UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[xVoJKSzVyPUKuNlU5ODdizszN MnzZV2FPT0WU
LU-134-A NGrEOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD1{LkK3O{DPxE1? NFzEVW5USU6JRWK=
CP66-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:3S2lEPTB;Mj6yPVAyPCEQvF2= MYnTRW5ITVJ?
HCC1143 NInROVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rTbWlEPTB;Mj60OVM3QCEQvF2= M4jxcHNCVkeHUh?=
LOXIMVI M3z4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXTWM2OD1{Lk[wNlEh|ryP NIrvdo9USU6JRWK=
TE-10 NVeyWoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwN{C4N|gh|ryP MUXTRW5ITVJ?
NCI-H1882 NIjsWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vP[mlEPTB;Mj63OVIzPyEQvF2= NEDC[3NUSU6JRWK=
CHP-126 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorGTWM2OD1{Lke2N|E4KM7:TR?= MVTTRW5ITVJ?
NCI-H1623 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rwV2lEPTB;Mj65NlAzPCEQvF2= M2\nZXNCVkeHUh?=
GB-1 M2[wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrqTWM2OD1{LkmzOFA1KM7:TR?= MVHTRW5ITVJ?
RCC10RGB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TDfWlEPTB;Mj65OVI5OSEQvF2= NEjSN45USU6JRWK=
NCI-H2141 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv1VZFKSzVyPUKuPVY5QTZizszN M{\NOXNCVkeHUh?=
GI-ME-N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELrfmFKSzVyPUOuNFA2PjVizszN NUW2U|R[W0GQR1XS
NCI-H526 NHrSO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjSphKSzVyPUOuNFQxQDVizszN MmH6V2FPT0WU
NCI-H747 NFfYcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vaS2lEPTB;Mz6wOFk6OiEQvF2= Mo\xV2FPT0WU
SNU-423 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fEVGlEPTB;Mz6yNFMyOyEQvF2= NYG4fW9FW0GQR1XS
A427 NV;pcW81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u1UmlEPTB;Mz6yOVY6QSEQvF2= NH;vOGlUSU6JRWK=
CAL-12T NU\Wc2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwNEC3NVMh|ryP M4nqdHNCVkeHUh?=
LU-99A M4Sw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInwbG5KSzVyPUOuOFcyODVizszN MVHTRW5ITVJ?
MS-1 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjMUFZKSzVyPUOuOVM1OjlizszN MojsV2FPT0WU
SK-LU-1 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPuTWM2OD1|Lke2Nlk2KM7:TR?= NH3mVYZUSU6JRWK=
SW837 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwN{[zN|Mh|ryP MoCxV2FPT0WU
ES8 NGnZWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Lb45uUUN3ME2zMlg{QDd5IN88US=> NHzOWIVUSU6JRWK=
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPMfmtTUUN3ME2zMlkzODh4IN88US=> M2X5VHNCVkeHUh?=
TGW MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXzXJNRUUN3ME20MlAyOzFzIN88US=> M2LZXHNCVkeHUh?=
GP5d NVr3[XF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwMEWzOlIh|ryP M2TzbnNCVkeHUh?=
BB49-HNC M3n2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzl[4ZKSzVyPUSuNVUzOTNizszN MlHWV2FPT0WU
NB13 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36N2NKSzVyPUSuNlY5QDdizszN NEHhXHRUSU6JRWK=
NTERA-S-cl-D1 M3LxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;MTYxQUUN3ME20MlI5PjF3IN88US=> NVHPSlQ5W0GQR1XS
NCI-H1648 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXmTWM2OD12LkK5PFE6KM7:TR?= NGDuNZFUSU6JRWK=
LCLC-103H NVy5d41KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHxVplQUUN3ME20MlMzOTl3IN88US=> NVr2eYk5W0GQR1XS
LS-411N NHHtTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ZTWM2OD12LkS0PFg2KM7:TR?= NEniRZRUSU6JRWK=
NCI-H1092 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsTWM2OD12LkS1Olg4KM7:TR?= M4rRXHNCVkeHUh?=
PANC-10-05 M{XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwNkm4OEDPxE1? M4HrT3NCVkeHUh?=
DK-MG M3;GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRwOEC5N|Mh|ryP M3Lhe3NCVkeHUh?=
OVCAR-5 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Hb4xKSzVyPUSuPFEzOjZizszN NHjPToFUSU6JRWK=
CAL-39 M3Tie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnwTWM2OD12Lki3Olch|ryP NWrOTGh6W0GQR1XS
TE-441-T M13NRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C1VWlEPTB;ND65NFU{PyEQvF2= NXjZZY5GW0GQR1XS
MOLT-16 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0[HpDUUN3ME20Mlk2OjV|IN88US=> Mnq1V2FPT0WU
MCF7 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\mbmlEPTB;NT6xOFUyPyEQvF2= M3HJZ3NCVkeHUh?=
CAPAN-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTVwMkW3NFch|ryP Ml\uV2FPT0WU
PSN1 NHfrVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrqTWM2OD13LkK3NlM2KM7:TR?= Mon0V2FPT0WU
NCI-H292 NVzUbJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwM{CwOFQh|ryP NHyyTZJUSU6JRWK=
CPC-N Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2myRWlEPTB;NT6zPVQyQSEQvF2= MX7TRW5ITVJ?
DoTc2-4510 M2LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwNEWzO|Eh|ryP MnnSV2FPT0WU
LB1047-RCC NUnXN5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTVwNUW5N|Mh|ryP M1XkTnNCVkeHUh?=
MHH-ES-1 M2\6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rUXWlEPTB;NT61PVkxPyEQvF2= NFjjSXlUSU6JRWK=
NMC-G1 M2H0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwN{CyNlch|ryP NU\K[|l3W0GQR1XS
SW1710 NHTVOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTVwN{S3OVEh|ryP MYDTRW5ITVJ?
YAPC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVwN{[yNFEh|ryP NX3HNWVYW0GQR1XS
22RV1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTVwOECwNVkh|ryP NIHNZ2RUSU6JRWK=
COLO-679 NFHpOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTVwOEi5OFgh|ryP MXHTRW5ITVJ?
TCCSUP MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfQfnhKSzVyPUWuPVMzPTlizszN NGrh[YNUSU6JRWK=
C2BBe1 NWXXN4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXETWM2OD13LkmzPVch|ryP NGXBRnpUSU6JRWK=
TE-15 NWW3cmo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTZwME[2NFUh|ryP NGLCRZNUSU6JRWK=
SCLC-21H NFvBSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPYbnpqUUN3ME22MlExQDR|IN88US=> NHTI[lhUSU6JRWK=
EoL-1-cell NY\xUXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX1WXVQUUN3ME22MlE3PTZ|IN88US=> M{fOTHNCVkeHUh?=
NKM-1 NIT1ZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiXXZKSzVyPU[uNVY4OSEQvF2= M1Lnc3NCVkeHUh?=
NCI-H1304 NFux[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwMke0Nlgh|ryP MYfTRW5ITVJ?
NB6 M3L1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7FUoFKSzVyPU[uNlk3OjJizszN MkjMV2FPT0WU
NALM-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPhTWM2OD14LkOzNlMh|ryP Ml\0V2FPT0WU
NCI-H522 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rKZmlEPTB;Nj6zN|MxPiEQvF2= NYS4V5hUW0GQR1XS
MV-4-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwM{ewO|kh|ryP MVfTRW5ITVJ?
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vuT2lEPTB;Nj6zPFY3PyEQvF2= MkL4V2FPT0WU
NCI-H1417 NHTnNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv5TWM2OD14LkSwPFQ4KM7:TR?= MVTTRW5ITVJ?
HT-1197 M4P4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwNUexNlIh|ryP M3\ZPHNCVkeHUh?=
P30-OHK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq5WnRKSzVyPU[uOlI4PyEQvF2= NFP0e3lUSU6JRWK=
ALL-PO MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYPZc1UUN3ME22MlcyQTF4IN88US=> NVLKVWxwW0GQR1XS
OVCAR-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFV45KSzVyPU[uO|U1ODVizszN MW\TRW5ITVJ?
HCC2157 NX71ZWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rWdGlEPTB;Nj63O|Q4PSEQvF2= MYnTRW5ITVJ?
NCI-H838 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZwOU[0PUDPxE1? NEfkR4VUSU6JRWK=
NCI-H1299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j5fmlEPTB;Nj65O|A6KM7:TR?= MoLRV2FPT0WU
SW954 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T6c2lEPTB;Nz6yNFA3QCEQvF2= M1HuSnNCVkeHUh?=
NCI-H441 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFVWhtUUN3ME23MlM1ODZ3IN88US=> MWTTRW5ITVJ?
SK-MEL-2 NV\QSXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\MWVJKSzVyPUeuOFg{PzNizszN MYnTRW5ITVJ?
KARPAS-45 NGjFWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\hTWM2OD15Lk[1PVI6KM7:TR?= NXLl[5RJW0GQR1XS
CAL-54 NGPxRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPLNmxKSzVyPUeuPFI6PzdizszN MojjV2FPT0WU
KYSE-180 NVexbW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHoTWM2OD15Lki4PVQyKM7:TR?= NWS3VJpyW0GQR1XS
NCI-H187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzUR5hKSzVyPUeuPVU6PDdizszN NX:yTJdGW0GQR1XS
RT-112 M3Xvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBOYxKSzVyPUiuNFk3PzdizszN MUfTRW5ITVJ?
NCI-H1437 M4nsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrbXhKSzVyPUiuNFk4QTVizszN M1LQfXNCVkeHUh?=
SNU-449 NHG5V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i0WWlEPTB;OD6yPFI4OiEQvF2= MmHIV2FPT0WU
HCC1187 NX\JZllMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsUFRKSzVyPUiuNlk{QTFizszN NX[z[Ih4W0GQR1XS
NCI-H2030 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwM{e3NVQh|ryP NVrSUJREW0GQR1XS
HuO-3N1 NYq5Vm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRThwM{e4OFQh|ryP NULpc3dlW0GQR1XS
COLO-792 NFLWTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRThwNEG1Nlch|ryP MVnTRW5ITVJ?
MIA-PaCa-2 NH\FTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW1bWFKSzVyPUiuPFU2ODhizszN NVP3THF2W0GQR1XS
SK-N-FI MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jKWGlEPTB;OT6wOFI2KM7:TR?= MYjTRW5ITVJ?
MMAC-SF NVruSpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj0Sng1UUN3ME25MlA6PzVzIN88US=> M2PEPHNCVkeHUh?=
NCI-H28 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBdFVKSzVyPUmuNVA1PjlizszN NXXj[4lvW0GQR1XS
ETK-1 NWTYZZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPxVZRKSzVyPUmuNlk6PzRizszN NVWyWG1TW0GQR1XS
NCI-H1993 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTlwNESyOlEh|ryP NUjTUmtUW0GQR1XS
no-11 NYfGTHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PKTGlEPTB;OT60O|EzKM7:TR?= M3XqcnNCVkeHUh?=
ChaGo-K-1 NXGwcVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHUTWM2OD17LkWxOVg{KM7:TR?= NGLqXVRUSU6JRWK=
NCCIT M2jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjDO2lpUUN3ME25MlU{OTZ7IN88US=> NHHHTVdUSU6JRWK=
SAS NYTJUphTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFyLkK0PEDPxE1? NXzlTFBZW0GQR1XS
A673 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\pNWlEPTB;MUCuN|cxPCEQvF2= M{X0WHNCVkeHUh?=
NCI-H1522 M2PsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzDOZNkUUN3ME2xNE4{PzB5IN88US=> NVPTNFZiW0GQR1XS
NCI-H810 NEntOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr0Wll5UUN3ME2xNE4{QTB5IN88US=> M1PTcHNCVkeHUh?=
IST-MES1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf1U4tKSzVyPUGwMlQ2PjRizszN M2fH[3NCVkeHUh?=
GR-ST MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Z[YtsUUN3ME2xNE42ODJ2IN88US=> NIG0N49USU6JRWK=
SUP-T1 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLZXJhNUUN3ME2xNE44OzF5IN88US=> NXzxUmFGW0GQR1XS
NB5 M4\od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFyLkmwNlIh|ryP M{nQO3NCVkeHUh?=
MZ1-PC M2GzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFyLkm1O|Eh|ryP M2PTcHNCVkeHUh?=
SK-CO-1 NFG4WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0XINwUUN3ME2xNE46QTNzIN88US=> MVjTRW5ITVJ?
Capan-2 NVn6fnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTpOndKSzVyPUGxMlMyQThizszN NYezfodrW0GQR1XS
697 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0TWM2OD1zMT62O|U4KM7:TR?= NFnPd2lUSU6JRWK=
REH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPVbpRKSzVyPUGxMlc1PTFizszN NGPldJRUSU6JRWK=
GI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37xfWlEPTB;MUGuPFYyPSEQvF2= MmHtV2FPT0WU
BB65-RCC NWS3OXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn4Xm5KSzVyPUGyMlA6OTZizszN Ml7sV2FPT0WU
NCI-H1651 NH3PbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHZUGVKSzVyPUGyMlI1PzhizszN NEnYO3ZUSU6JRWK=
NCI-H1618 M1nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnnTWM2OD1zMj6zPVc3KM7:TR?= NXTH[|Q3W0GQR1XS
NCI-H2081 M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrWb|VKSzVyPUGyMlYyPDFizszN MXrTRW5ITVJ?
GCIY NVXNR5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDRenRKSzVyPUGyMlczOTNizszN M2j3OHNCVkeHUh?=
NY NWHLR25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFdWlEPTB;MUOuNFY1OyEQvF2= MmT0V2FPT0WU
PANC-03-27 NX;YNVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3xdGZ{UUN3ME2xN{4xQDB5IN88US=> MmruV2FPT0WU
BHY MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD1zMz6yNVIyKM7:TR?= MV3TRW5ITVJ?
SK-OV-3 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsfmlEPTB;MUOuN|c3OyEQvF2= MVvTRW5ITVJ?
5637 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrwS4g1UUN3ME2xN{44PzV7IN88US=> MYfTRW5ITVJ?
LC-1F NUfmeHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe1fFZKSzVyPUG0MlA{PTZizszN NX:3V2I6W0GQR1XS
SNB75 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD1zND6wN|g{KM7:TR?= MYnTRW5ITVJ?
CHP-212 M{iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPRTWM2OD1zND6wOFY1KM7:TR?= MlTjV2FPT0WU
HT-1376 NXm5S3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTYcGlOUUN3ME2xOE4yOTJ4IN88US=> M4TQPXNCVkeHUh?=
MONO-MAC-6 NYHifJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfjTWM2OD1zND6xOVAzKM7:TR?= Ml3aV2FPT0WU
CA46 M4XsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjWXJJKSzVyPUG0MlE5OjdizszN MV3TRW5ITVJ?
SCC-15 NXPzS495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPvS21KSzVyPUG0MlU2QDNizszN NIfWWHlUSU6JRWK=
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1dYZKSzVyPUG0MlY3OjdizszN NGfRWI1USU6JRWK=
NCI-H2405 M2DSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;QVlg3UUN3ME2xOE45OTV5IN88US=> MWjTRW5ITVJ?
NCI-H716 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkUW1KSzVyPUG0Mlg1QTNizszN NHq0XZpUSU6JRWK=
SW620 NEn3N29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3YV2JKSzVyPUG0MlkxOTRizszN NV2yeI16W0GQR1XS
NCI-H226 NVi3fXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF2LkmwPFUh|ryP MkHtV2FPT0WU
SW962 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF2Lkm0N|Ih|ryP NVTqXlhsW0GQR1XS
KYSE-150 NHLPfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;vTWlEPTB;MUSuPVU2KM7:TR?= MkLzV2FPT0WU
OCUB-M NI\RW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LXe2lEPTB;MUSuPVg5OyEQvF2= NIXBTWRUSU6JRWK=
ES7 M4TMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\1d2dKSzVyPUG1MlA6QDRizszN NXXCSlJzW0GQR1XS
SW1463 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF3LkSyNlMh|ryP NF7Wd45USU6JRWK=
CAKI-1 M2TGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP1TWM2OD1zNT61N|Q3KM7:TR?= MV;TRW5ITVJ?
MKN28 M4fWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1bIZNUUN3ME2xOU42PDd7IN88US=> MX;TRW5ITVJ?
SW13 NILHcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LtfmlEPTB;MUWuOlE5KM7:TR?= M4DmVHNCVkeHUh?=
A3-KAW M17KSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D4O2lEPTB;MUWuPVY6PyEQvF2= M1LycHNCVkeHUh?=
LU-65 NUT2RZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK5eIhKSzVyPUG1Mlk4PjhizszN MVzTRW5ITVJ?
Calu-1 NUfKXotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFcmlEPTB;MU[uNFM3QCEQvF2= MlXjV2FPT0WU
ST486 M2HuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17hVGlEPTB;MU[uNFQ{OSEQvF2= MXHTRW5ITVJ?
BB30-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD1zNj6xNlQ3KM7:TR?= NHzLbGRUSU6JRWK=
EGI-1 NWPtN49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm4TWM2OD1zNj60OFYh|ryP NHHzV|JUSU6JRWK=
SH-4 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLZ2lEPTB;MU[uOFc{OSEQvF2= Ml7KV2FPT0WU
MN-60 NInqXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\wVmlEPTB;MUeuNlI6PyEQvF2= MW\TRW5ITVJ?
MPP-89 NUPWRnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\2dHF{UUN3ME2xO{4zPDV7IN88US=> NXjEUVlzW0GQR1XS
A2780 NHLCPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnTTWM2OD1zNz60NVM6KM7:TR?= Mlq5V2FPT0WU
Daoy MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF5LkS2PVUh|ryP M1nscXNCVkeHUh?=
NCI-H2126 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1zNz60O|cyKM7:TR?= MYnTRW5ITVJ?
NCI-H1563 M2fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvJTWM2OD1zNz60PVE4KM7:TR?= MkfTV2FPT0WU
8-MG-BA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF5Lk[2OFgh|ryP MYXTRW5ITVJ?
786-0 NIrhTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:1TWM2OD1zNz64N|U{KM7:TR?= MmXuV2FPT0WU
AM-38 NEHmVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M334N2lEPTB;MUeuPVMxPiEQvF2= Mli5V2FPT0WU
COLO-824 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D2cGlEPTB;MUiuOFQ{PiEQvF2= M1:0[3NCVkeHUh?=
SK-MEL-30 NIi5VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG2TIVKSzVyPUG4MlUxQDJizszN NUHERlJyW0GQR1XS
CESS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j1N2lEPTB;MUiuO|YxQSEQvF2= NGLUUo5USU6JRWK=
BL-70 NV\IOZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PJR2lEPTB;MUiuPFE2PiEQvF2= M3zTNXNCVkeHUh?=
NCI-H2170 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;6cJpqUUN3ME2xPE46OTd7IN88US=> M3jl[3NCVkeHUh?=
HT-3 NYHkdHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF6Lkm4N{DPxE1? NVuzN41sW0GQR1XS
BOKU NWXvOoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHITWM2OD1zOT6wN|gyKM7:TR?= NGPLNVlUSU6JRWK=
HPAF-II NXfFeZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrtWHllUUN3ME2xPU4{ODF3IN88US=> M1rsd3NCVkeHUh?=
KGN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe5RZpKSzVyPUG5MlQ4PjVizszN M3nQbXNCVkeHUh?=
MC-CAR M3XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfMTWM2OD1zOT62N|E{KM7:TR?= MX3TRW5ITVJ?
BHT-101 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXhTWM2OD1zOT63O|ch|ryP NXHiSZJCW0GQR1XS
SW1783 NYf2NIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF7Lke4NFYh|ryP NHyzNFVUSU6JRWK=
KP-N-YN NUDjdZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1njdmlEPTB;MkCuNFI3OiEQvF2= NI\2cmtUSU6JRWK=
LU-165 NXq0R3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XhfmlEPTB;MkCuOVU4OSEQvF2= MmXPV2FPT0WU
GOTO M1j2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJyLk[0OVEh|ryP M{L3dXNCVkeHUh?=
EFM-19 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXsU4MyUUN3ME2yNU4xPzF4IN88US=> MmLFV2FPT0WU
CTV-1 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJzLkGwOVQh|ryP M4jqc3NCVkeHUh?=
HEL NGXqbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJzLkSyNVYh|ryP MknjV2FPT0WU
SNU-C2B M{fQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDkTWM2OD1{MT60NlYh|ryP NGPDUFFUSU6JRWK=
ECC4 M{OyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJzLkewO{DPxE1? NUjITFlPW0GQR1XS
NEC8 M{S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJzLkizOlgh|ryP M3\sR3NCVkeHUh?=
KMOE-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLRTWM2OD1{MT64PVIyKM7:TR?= NYXQc5JZW0GQR1XS
NCI-H524 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ{LkC4NFgh|ryP NGP6VWFUSU6JRWK=
WSU-NHL NEXjeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTmbnFKSzVyPUKyMlE2PzdizszN M4jvfXNCVkeHUh?=
SF126 NUe2eJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ{LkK0Olkh|ryP MnLrV2FPT0WU
HOP-92 M1HFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLPHA{UUN3ME2yNk4{OTZ5IN88US=> M4W1OnNCVkeHUh?=
CTB-1 NY\5dXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ubG9KSzVyPUKyMlQ3PzdizszN M1;xZ3NCVkeHUh?=
KYSE-270 M3jZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm1cnpKSzVyPUKyMlk{PTdizszN NVrrWXJHW0GQR1XS
SK-MEL-24 NYn4b5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj3cGRKSzVyPUKzMlE5PyEQvF2= NIjQT4VUSU6JRWK=
Calu-3 NYrxfWVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLuTWM2OD1{Mz6yNVI5KM7:TR?= MUjTRW5ITVJ?
GAMG MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHEO|dzUUN3ME2yN{4zOzZ5IN88US=> Mo\VV2FPT0WU
SW1573 M4rnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ|Lke0NVUh|ryP NUjTcJhXW0GQR1XS
MHH-NB-11 NXjpdXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ2LkCxPVQh|ryP M2XxbnNCVkeHUh?=
TK10 NXTyUGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r1SmlEPTB;MkSuOVAyOyEQvF2= M4Pae3NCVkeHUh?=
LB373-MEL-D MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ2Lk[wOlQh|ryP M3i0WHNCVkeHUh?=
KALS-1 NEnZS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj6WHU6UUN3ME2yOE44OzJ5IN88US=> NHnDTldUSU6JRWK=
HUTU-80 NVnib25UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkThTWM2OD1{NT64NFMzKM7:TR?= NInQWVFUSU6JRWK=
HuP-T3 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDXTWM2OD1{Nj6xOlc1KM7:TR?= NV7JRlkzW0GQR1XS
OE19 M2fQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHoZ4VKSzVyPUK2MlIyPTNizszN NIfoNWJUSU6JRWK=
J82 NFvzS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm3e|hKSzVyPUK2MlI1PzFizszN MVzTRW5ITVJ?
DU-4475 M2qwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPYR41KSzVyPUK2MlM5OTlizszN M1PBbHNCVkeHUh?=
DMS-53 M2rOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7pUGVKSzVyPUK2MlUyOzhizszN NWfrVWJvW0GQR1XS
COLO-741 M3TucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvVT25KSzVyPUK2Mlg{PDRizszN MnOxV2FPT0WU
SW48 NFT0bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjHRZJ5UUN3ME2yOk45QDJizszN NF7VWIFUSU6JRWK=
IGR-1 NUnOdYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fQc2lEPTB;Mk[uPVM{PCEQvF2= NXPzSHNPW0GQR1XS
639-V Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrGbYdUUUN3ME2yO{4xOjR3IN88US=> M13TTXNCVkeHUh?=
LK-2 M4TEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ5LkSxOFEh|ryP M4\2ZXNCVkeHUh?=
NCI-H2347 NHnsXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPIbYZKSzVyPUK3Mlk3QTlizszN NE\WT|RUSU6JRWK=
NCI-H2228 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ6LkC5NFUh|ryP M3jWe3NCVkeHUh?=
LS-123 NUX4S4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rIV2lEPTB;MkiuNVI3OiEQvF2= NEfTTItUSU6JRWK=
U031 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDydJVEUUN3ME2yPE4zPTJizszN M{LKOXNCVkeHUh?=
NCI-H1792 NYjFT|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1{OD60O|IyKM7:TR?= NHi3NllUSU6JRWK=
NCI-H2087 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ6Lke1OVIh|ryP MVvTRW5ITVJ?
NCI-H2342 M3vycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ7LkWyNFgh|ryP NVvxfINSW0GQR1XS
SW626 NH;NXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnmTnBKSzVyPUK5Mlc2PiEQvF2= NXzEWodVW0GQR1XS
LB2518-MEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG4TWM2OD1{OT64NVUh|ryP MUjTRW5ITVJ?
RXF393 NFfQ[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXwTWM2OD1|MD6wPVUzKM7:TR?= MWjTRW5ITVJ?
LC4-1 NUTkPVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nRZmlEPTB;M{CuN|A6OiEQvF2= NIf0NG5USU6JRWK=
NCI-H1694 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPIZmZKSzVyPUOwMlY3OjRizszN NILhS|JUSU6JRWK=
K5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPETWM2OD1|MD65O|AzKM7:TR?= MWDTRW5ITVJ?
HDLM-2 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNyLkm3NlUh|ryP NUfsNJVxW0GQR1XS
BCPAP NIPkTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX2TWM2OD1|MT64N|c6KM7:TR?= MUHTRW5ITVJ?
BC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hTWM2OD1|Mj6xOFA{KM7:TR?= NUS0bY1vW0GQR1XS
LB996-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\nTWM2OD1|Mj6yN|U5KM7:TR?= M3TpT3NCVkeHUh?=
NCI-H2009 NGnD[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxTWM2OD1|Mj60PVgyKM7:TR?= NE\nZYZUSU6JRWK=
HTC-C3 NEDHNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHBc5d3UUN3ME2zN{44PTF7IN88US=> MYfTRW5ITVJ?
LAMA-84 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTTdnFLUUN3ME2zOE41PDB5IN88US=> NHL3dYVUSU6JRWK=
CCRF-CEM M2rqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPQRVd6UUN3ME2zOE42PzF3IN88US=> MlPZV2FPT0WU
AN3-CA MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfKVllGUUN3ME2zOU4xPTZ6IN88US=> MljyV2FPT0WU
NCI-H1734 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTyZYxKSzVyPUO1MlI2PjFizszN M3HmUnNCVkeHUh?=
Ca-Ski M4rjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN3LkSxNFEh|ryP NHzJXndUSU6JRWK=
U-266 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO1XWRKSzVyPUO1MlYyOTRizszN NYrNdYFnW0GQR1XS
SBC-5 NFPxOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN3Lke3PFEh|ryP NGPmTFFUSU6JRWK=
GT3TKB NEi1cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ztS2lEPTB;M{euNVE2KM7:TR?= MoLtV2FPT0WU
MDA-MB-175-VII NFLhc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLuTWM2OD1|Nz6yNlQ5KM7:TR?= Mnn0V2FPT0WU
PFSK-1 NGnjVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnGW|I{UUN3ME2zO{4zPDN3IN88US=> MWfTRW5ITVJ?
IMR-5 M{i1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfxfJhKSzVyPUO3MlI1QDdizszN NIq5dopUSU6JRWK=
Daudi MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN5LkO1PVch|ryP M1vqXXNCVkeHUh?=
A498 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX5TWM2OD1|Nz63NlE5KM7:TR?= M2LH[HNCVkeHUh?=
SCC-4 NUfmO4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG4ZZhrUUN3ME2zO{44QDR|IN88US=> NWfSSHZDW0GQR1XS
COLO-680N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\tR2lEPTB;M{iuNlg5PSEQvF2= MWLTRW5ITVJ?
SK-MES-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vnRWlEPTB;M{iuN|IyPSEQvF2= NVHKTZVKW0GQR1XS
SR NFvSfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C0eWlEPTB;M{iuOVQ6PSEQvF2= NVLzUGpNW0GQR1XS
LNCaP-Clone-FGC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DPd2lEPTB;M{iuOVY{PyEQvF2= NFLTfppUSU6JRWK=
SK-HEP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[zTWM2OD1|OD63PFIzKM7:TR?= M{i5OnNCVkeHUh?=
BPH-1 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XYXWlEPTB;M{iuPFMzQSEQvF2= Mn\CV2FPT0WU
NCI-H1755 NXL2TlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTN7LkW4NVch|ryP NIPtXJZUSU6JRWK=
LXF-289 M3LUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr4OllRUUN3ME2zPU45ODh2IN88US=> M{HQZ3NCVkeHUh?=
SW1088 NXvnd4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWd|lKSzVyPUSwMlIyODdizszN NUmwe2NzW0GQR1XS
MOLT-4 M3;kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTdmlEPTB;NECuNlkxOSEQvF2= M{jYbHNCVkeHUh?=
AsPC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSySG44UUN3ME20NE41PTh|IN88US=> NYHxZZVVW0GQR1XS
HOP-62 M3\0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonuTWM2OD12MD62OVY5KM7:TR?= M4\j[nNCVkeHUh?=
A172 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32x[mlEPTB;NECuPFUyOSEQvF2= NVL1THhkW0GQR1XS
SN12C NX7FS4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFb2lEPTB;NECuPVM5PSEQvF2= M3LOSnNCVkeHUh?=
MDA-MB-231 M1v0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpUmJKSzVyPUSwMlk5QThizszN Mn\RV2FPT0WU
RPMI-2650 M4T3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHWTWM2OD12MT6xOVk{KM7:TR?= MYPTRW5ITVJ?
KYSE-140 NVywWW5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV65T45LUUN3ME20NU45OTJ|IN88US=> NUXsTWliW0GQR1XS
KINGS-1 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fsWmlEPTB;NEKuOFY6PyEQvF2= M3XETnNCVkeHUh?=
HSC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljvTWM2OD12Mj62OlYyKM7:TR?= M3mwPHNCVkeHUh?=
PC-14 NEDLeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2OGlEPTB;NEOuNVg5OiEQvF2= M1rscnNCVkeHUh?=
COR-L105 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNTWM2OD12Mz62OVAzKM7:TR?= Mk\BV2FPT0WU
BE-13 NYfpSHEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTGeJQ3UUN3ME20OE4zOzdzIN88US=> M2O4b3NCVkeHUh?=
NCI-H661 M{nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR2LkK5OVgh|ryP MYLTRW5ITVJ?
IST-MEL1 NX3sNIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HofWlEPTB;NESuN|U6QSEQvF2= NV3Wb2hZW0GQR1XS
HCC1806 NX3aZ|dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTR2LkW4O|Mh|ryP NVjG[FF{W0GQR1XS
COLO-800 NUTm[VJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33z[WlEPTB;NESuPFQ2OyEQvF2= NWPDZ5d6W0GQR1XS
IST-SL2 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P4UmlEPTB;NEWuNVI1PyEQvF2= NYThSnJYW0GQR1XS
8305C M1\KT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTrTWM2OD12NT6zNFkh|ryP MVjTRW5ITVJ?
UACC-62 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rLSWlEPTB;NE[uNlg4PSEQvF2= MnLBV2FPT0WU
COR-L23 NIfrWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmyR3Y4UUN3ME20O{4yQTlizszN NXjaSJlMW0GQR1XS
EFE-184 M4jMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tTWM2OD12Nz6zPFgh|ryP M{fmPHNCVkeHUh?=
DMS-114 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTDTWM2OD12Nz60NVQ6KM7:TR?= M4O5dHNCVkeHUh?=
KYSE-520 NHPpc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfBfndUUUN3ME20PE42OzF3IN88US=> NXLYSXN{W0GQR1XS
SNG-M MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXqeWtKSzVyPUS5MlQ{PCEQvF2= NI\hWFJUSU6JRWK=
A2058 NFvwR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjRTlNUUUN3ME20PU41QDh3IN88US=> MlvDV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib|Linsitinib ic50|Linsitinib price|Linsitinib cost|Linsitinib solubility dmso|Linsitinib purchase|Linsitinib manufacturer|Linsitinib research buy|Linsitinib order|Linsitinib mouse|Linsitinib chemical structure|Linsitinib mw|Linsitinib molecular weight|Linsitinib datasheet|Linsitinib supplier|Linsitinib in vitro|Linsitinib cell line|Linsitinib concentration|Linsitinib nmr|Linsitinib in vivo|Linsitinib clinical trial|Linsitinib inhibitor|Linsitinib Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID